Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    IS03 - Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges

    • 11:45 - 12:45
    • 1/28/2021
    • Location: Industry Symposia Auditorium (via Industry Hub)
    • Not for CME Credit
    • Type: Industry Symposium
    • Track:
    • +

      IS03.03 - Emerging ADC Targets for the Treatment of Late-Line NSCLC

      12:00 - 12:15  |  Presenter: Pasi Antero Jänne

      • Abstract

      No abstract available for this presentation

  • +

    FP01 - Early Stage/Localized Disease

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Early Stage/Localized Disease
    • +

      FP01.05 - The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC

      00:00 - 00:00  |  Presenter: Andrew Piper-Vallillo

      • Abstract

      Loading...

  • +

    P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      P01.03 - Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC

      00:00 - 00:00  |  Presenter: Pasi Antero Jänne

      • Abstract

      Loading...

    • +

      P01.04 - Dynamics of Molecular Markers in EGFR-Mutated NSCLC Patients Treated with Patritumab Deruxtecan (HER3-DXd; U3-1402)

      00:00 - 00:00  |  Presenter: Pasi Antero Jänne

      • Abstract

      Loading...

  • +

    P34 - Pathology - Liquid Biopsy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
    • +

      P34.04 - Circulating Tumor DNA (ctDNA) as a Marker of Progressive Disease in Patients with Advanced Lung Cancer 

      00:00 - 00:00  |  Presenter: Bryan C Ulrich

      • Abstract

      Loading...

  • +

    OA04 - New Data from Rare EGFR Alterations

    • 11:45 - 12:45
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

      11:45 - 11:55  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01

      12:05 - 12:15  |  Presenter: Kazuhiko Nakagawa

      • Abstract

      Loading...

  • +

    PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 07:00 - 09:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS01.08 - Discussant

      08:00 - 08:08  |  Presenter: Pasi Antero Jänne

      • Abstract

      No abstract available for this presentation

  • +

    PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 18:00 - 20:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS02.08 - Discussant

      19:00 - 19:08  |  Presenter: Pasi Antero Jänne

      • Abstract

      No abstract available for this presentation

  • +

    MA11 - Expanding Targetable Genetic Alterations in NSCLC

    • 14:15 - 15:15
    • 1/31/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      MA11.03 - Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01

      14:15 - 14:20  |  Presenter: Egbert F Smit

      • Abstract

      Loading...